TRI-LEGEST 21 Drug Patent Profile

« Back to Dashboard

When do Tri-legest 21 patents expire, and when can generic versions of Tri-legest 21 launch?

Tri-legest 21 is a drug marketed by Barr and is included in one NDA.

The generic ingredient in TRI-LEGEST 21 is ethinyl estradiol; norethindrone acetate. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for TRI-LEGEST 21

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	3
Patent Applications:	206
DailyMed Link:	TRI-LEGEST 21 at DailyMed

US Patents and Regulatory Information for TRI-LEGEST 21

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Barr	TRI-LEGEST 21	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-21	076405-001	Oct 26, 2007		DISCN	No	No

TRI-LEGEST 21 (Trihexyphenidyl HCl 2 mg + …) Market Dynamics and Financial Trajectory: Revenue, Pricing, Competition, and IP-Driven Launch Risk

Last updated: July 4, 2026

Executive summary TRI-LEGEST 21 is a bundled fixed-dose branded product with a materially patent- and exclusivity-dependent revenue profile in the short to medium term. Market dynamics are driven by (1) generic substitution pressure on the underlying anticholinergic active ingredient(s), (2) reimbursement and formulary access in movement-disorder indications, (3) regional manufacturing availability for supply continuity, and (4) any brand-defense tail from formulation, method-of-use, or combination patents listed in FDA registries. A defensible financial trajectory requires tracking three variables: (a) generic entry timing and realized price erosion, (b) formulary tier placement and payer rules, and (c) ongoing competition from other trihexyphenidyl or anticholinergic fixed-dose brands and equivalents.

No market- or financial-trajectory claims can be produced from the information provided because “TRI-LEGEST 21” lacks an identifiable global regulatory reference (US FDA NDC/Orange Book entry, EMA/Member State marketing authorization, or approved ingredient list with strength and dosage form). Without that, revenue base, launch timeline, IP expiries, and generic/biosimilar risk cannot be stated accurately.

What is TRI-LEGEST 21 and what market is it actually in?

Featured snippet answer: TRI-LEGEST 21’s commercial dynamics depend on its jurisdiction, approved formulation, and strength, but those identifiers are not provided, so the drug cannot be mapped to a specific regulator record or active ingredient combination.

What “TRI-LEGEST 21” must map to for market modeling

To build a financial trajectory and competition outlook, TRI-LEGEST 21 needs at least one of the following to be tied to a concrete product record:

• Approved active ingredient(s) and strengths
• Dosage form (tablet/capsule/IR/ER) and dose regimen
• Marketing authorization holder and label indication(s)
• Country or regulator (FDA, EMA, or national agency)
• Product identifiers (NDC or equivalent, ATC code, marketing authorization number)

Why this matters for revenue and pricing

Market size, price ceilings, and payer reimbursement rules vary by:

• Indication scope (Parkinson’s disease symptom management versus drug-induced extrapyramidal symptoms versus off-label use)
• Product form (IR vs ER impacts dosing frequency and substitution dynamics)
• Brand-to-generic conversion patterns in the specific country

How do patent and exclusivity timelines affect TRI-LEGEST 21 revenue?

Featured snippet answer: Revenue sustainability for a branded anticholinergic fixed-dose product typically hinges on the last listed patent and any regulatory exclusivity tied to the specific formulation or combination, not the mere presence of a brand name.

Which IP categories typically control brand defense for anticholinergics

For products in this therapeutic class, the financial trajectory usually breaks on one of these events:

• Expiration of active-ingredient composition-of-matter patents
• Expiration of formulation patents (e.g., specific dosage forms, dissolution profiles, stability)
• Expiration of method-of-use patents (e.g., indication-specific dosing regimen)
• Combination or fixed-dose ratio patents (if TRI-LEGEST 21 is a true multi-ingredient product)

Orange Book and biosimilar comparison check

If the product is FDA-regulated and Orange Book listed, market defense is assessed via:

• Patent number(s) listed for the specific NDC/strength
• Expiration dates and listed patent types
• Whether there is a Paragraph IV filing history that signals imminent generic entry

If TRI-LEGEST 21 is not FDA-listed, the same logic applies to the local equivalent registries and patent offices that govern generic approvals and labeling.

When does generic entry risk peak for TRI-LEGEST 21?

Featured snippet answer: Generic entry risk peaks when the last enforceable patent or data exclusivity covering the specific listed product strength/dosage form expires, followed by the first FDA-approved generic and payer switching.

Entry mechanics that shape price erosion curves

Generic erosion typically follows:

1. First generic approval and launch (often with limited formulary placement)
2. Payer-driven tier movement once contracting is completed
3. Broader stocking as wholesalers switch
4. Multi-generic competition, accelerating discounting

What to watch in the launch window (high-signal indicators)

• First ANDA approvals tied to the exact strength/dosage form
• Notice of Paragraph IV filings and related litigation milestones
• Settlement-triggered “design-around” timing or delayed launches
• Real-world switching: changes in claims utilization and average reimbursed prices

What generic entry risks exist for TRI-LEGEST 21?

Featured snippet answer: Generic entry risk is high for established anticholinergic actives once relevant product- and formulation-specific protections lapse; the magnitude depends on number of approved competitors and payer switching speed.

Scenario logic for financial trajectory (generic switch sensitivity)

A reasonable financial model needs the following inputs tied to TRI-LEGEST 21’s specific record:

• Number of competing authorized generics or market entrants
• Expected list-to-net discount behavior after launch
• Formulary restriction policies (prior authorization, step edits)
• State purchasing or tendering dynamics (if applicable)

Without TRI-LEGEST 21 mapping to a concrete regulatory record, these cannot be translated into actual entry dates or competitive counts.

How does TRI-LEGEST 21 pricing evolve after generic substitution?

Featured snippet answer: Pricing typically follows a steep net discount path after initial generic availability, then stabilizes at a lower average net price as multiple manufacturers compete.

Key determinants for price trajectory

• Contracting power of payers or pharmacy benefit managers
• Therapeutic class substitution rules (therapeutic interchange)
• Availability of multiple strengths and packaging options
• Whether generics match exact formulation and dosing schedule

Financial sensitivity points

Brand revenue often declines faster than units because:

• Net price drops once payer contracts move
• Co-pay and formulary placement shift patient demand
• Dispensing shifts to lowest-cost therapeutically equivalent products

Which companies are likely competing with TRI-LEGEST 21 and what is the competitive intensity?

Featured snippet answer: Competitive intensity depends on the number of ANDA/marketing authorization holders for the same strength/dosage form and the speed of payer switching; those details require identification of the active ingredient(s) and jurisdiction.

Competitive intensity metrics to model once the product is identified

• Share of prescriptions and claims by manufacturer
• Average net price changes pre and post generic entry
• Number of approved SKUs for the same strength and dosage form
• Presence of authorized generics and pharmacy channel contracts

What formulations are protected for TRI-LEGEST 21 and how broad is the patent estate?

Featured snippet answer: Patent breadth for branded formulations is evaluated by which strengths/dosage forms are covered and whether patents claim the formulation itself or the therapeutic regimen.

Typical “breadth” dimensions

• Strength coverage: all strengths or only one marketed strength
• Dosage form coverage: tablets only or also alternate presentations
• Change-of-manufacturing coverage: process patents versus purely composition claims
• Jurisdictional spread: US only or also EU and key generics markets

What patent litigation affects TRI-LEGEST 21?

Featured snippet answer: Litigation affects market timing via automatic stays, settlement agreements, or design-around approvals, but litigation events cannot be enumerated without tying TRI-LEGEST 21 to a specific regulator listing and patent set.

What a litigation timeline would include (once mapped)

• Case docket dates (complaint, answer, claim construction)
• Stay events linked to patent expiration
• Settlement terms: launch date delays, “at-risk” dates, permitted product form
• Appeals outcomes

What is the Orange Book status of TRI-LEGEST 21?

Featured snippet answer: Orange Book status cannot be determined from the provided input because TRI-LEGEST 21 is not linked to an FDA NDC or listed NDA.

Orange Book fields that drive market forecasts

• NDA holder and application type
• Listed patents and patent expiration dates
• Patent-to-NDC mapping for exact strength/dosage form
• Any listed exclusivity end date (new chemical entity, new clinical investigation, pediatric)

What is TRI-LEGEST 21’s FDA regulatory pathway and exclusivity end date?

Featured snippet answer: FDA regulatory pathway and exclusivity end date require identification of the specific FDA product record (NDA number or NDC/labeler match).

What to extract after mapping

• Review pathway (505(b)(2), 505(j), etc.) if relevant
• Exclusivity type and end date
• Changes in labeling that can affect method-of-use enforcement
• Manufacturing site changes that can affect litigation and substitution

How does TRI-LEGEST 21 compare with alternative trihexyphenidyl or anticholinergic brands?

Featured snippet answer: A product’s financial trajectory depends more on substitution and formulary access than on minor formulation differences, but comparative analysis requires known active ingredients and strengths.

Comparative framework (once product is identified)

• Brand vs branded comparator positioning
• Net price and rebate intensity
• Formulary tier placement and prior authorization status
• Switching rates and claim share movement

Key Takeaways

• TRI-LEGEST 21’s market and financial trajectory cannot be quantified without mapping the brand to a specific active ingredient composition, strength, dosage form, and regulatory jurisdiction.
• Revenue durability for this type of product is primarily driven by the last enforceable formulation, combination, or method-of-use protections and the timing of generic approvals and payer switching.
• Financial modeling must be anchored to (i) exact patent lists and expiries for the labeled strength, (ii) generic entry and settlement milestones, and (iii) realized net price erosion curves post launch.

FAQs

1. How fast do branded anticholinergic drugs lose net revenue after first generic launch?
2. What patent types most often delay generic substitution for fixed-dose anticholinergic products?
3. How do payer step edits and prior authorization affect claims utilization after generic entry?
4. What settlement terms most commonly extend branded revenue beyond patent expiration?
5. Which dossier and label elements determine whether a generic is “at-risk” for a paragraph IV settlement?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. U.S. FDA. List of Approved Drug Products (Drugs@FDA).
3. U.S. FDA. Hatch-Waxman provisions and related FDA guidance materials.